AU2004258876B2 - Compositions containing prodrugs of florfenicol and methods of use - Google Patents

Compositions containing prodrugs of florfenicol and methods of use Download PDF

Info

Publication number
AU2004258876B2
AU2004258876B2 AU2004258876A AU2004258876A AU2004258876B2 AU 2004258876 B2 AU2004258876 B2 AU 2004258876B2 AU 2004258876 A AU2004258876 A AU 2004258876A AU 2004258876 A AU2004258876 A AU 2004258876A AU 2004258876 B2 AU2004258876 B2 AU 2004258876B2
Authority
AU
Australia
Prior art keywords
florfenicol
composition
ester prodrug
prodrug
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004258876A
Other languages
English (en)
Other versions
AU2004258876A1 (en
Inventor
Yerramilli Murthy
Robert H. Suva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of AU2004258876A1 publication Critical patent/AU2004258876A1/en
Application granted granted Critical
Publication of AU2004258876B2 publication Critical patent/AU2004258876B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2004258876A 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use Ceased AU2004258876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/623,114 2003-07-18
US10/623,114 US7439268B2 (en) 2003-07-18 2003-07-18 Compositions containing prodrugs of florfenicol and methods of use
PCT/US2004/021260 WO2005009429A1 (en) 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use

Publications (2)

Publication Number Publication Date
AU2004258876A1 AU2004258876A1 (en) 2005-02-03
AU2004258876B2 true AU2004258876B2 (en) 2009-02-26

Family

ID=34063306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004258876A Ceased AU2004258876B2 (en) 2003-07-18 2004-06-29 Compositions containing prodrugs of florfenicol and methods of use

Country Status (6)

Country Link
US (4) US7439268B2 (cg-RX-API-DMAC10.html)
EP (2) EP2181706A3 (cg-RX-API-DMAC10.html)
JP (1) JP2006528177A (cg-RX-API-DMAC10.html)
AU (1) AU2004258876B2 (cg-RX-API-DMAC10.html)
CA (1) CA2531223A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005009429A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
EP1696934B1 (en) * 2003-12-23 2013-05-29 Schering-Plough Ltd. Florfenicol prodrug having improved water solubility
WO2005066119A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Antibacterial 1-(4-mono-and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoropropanols and preparation thereof
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
US8168421B2 (en) 2005-12-09 2012-05-01 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
WO2008076261A2 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble phenicol prodrugs in a lipophilic vehicle system
CN101605756A (zh) * 2006-12-13 2009-12-16 先灵-普劳有限公司 氟苯尼考及其类似物的水溶性前药
PE20091171A1 (es) * 2007-12-14 2009-08-03 Schering Plough Ltd Proceso para recuperar florfenicol y analogos de florfenicol
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN104490882A (zh) * 2014-11-29 2015-04-08 郑州后羿制药有限公司 一种治疗鸭传染性浆膜炎疾病的中兽药及其制备方法
CN105111234B (zh) * 2015-09-23 2017-05-17 河北远征禾木药业有限公司 一种氟苯尼考磷酸酯的合成方法
CN108096191A (zh) * 2017-12-29 2018-06-01 河北利华药业有限公司 氟苯尼考预混剂及其制备方法
CN110787131B (zh) * 2019-12-13 2022-04-01 河北远征药业有限公司 一种氟苯尼考可溶性粉制剂的制备方法
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
CN111393341A (zh) * 2020-05-07 2020-07-10 中国农业大学 一种水溶性氟苯尼考氨基酸盐的制备方法
CN112345661B (zh) * 2020-10-21 2022-11-15 北京精益捷检测科技有限公司 一种兽药黄栀花口服液中氟苯尼考含量的测定方法
CN113416304B (zh) * 2021-06-22 2022-07-29 四川永诺生物科技有限公司 一种四臂聚乙二醇琥珀酸氟苯尼考化合物的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041899A1 (en) * 2000-11-27 2002-05-30 Phoenix Scientific, Inc. An antibiotic/analgesic formulation and a method of making this formulation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235692A (en) * 1972-01-24 1980-11-25 Townsend Douglas W Electrolytic apparatus
US4235892A (en) 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
ES488154A0 (es) * 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
IT1173213B (it) 1984-02-03 1987-06-18 Zambon Spa Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi
US4718800A (en) 1986-04-18 1988-01-12 General Signal Corporation Stanchion
FR2608607B1 (fr) * 1986-12-23 1989-04-28 Sanofi Sa Procede de preparation de thienylethylamines et dithienylethylamines ainsi obtenues
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
CA1267043A (en) * 1988-03-23 1990-03-27 Ernest J. Nagy Applicator device
US4876352A (en) 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5574020A (en) 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US5082883A (en) * 1990-03-12 1992-01-21 Eastman Kodak Company Reduced viscosity polyblends of polyester and epoxy resins
IT1240676B (it) * 1990-04-24 1993-12-17 Agrimont Spa Composizioni ad attivita' erbicida
US5082863A (en) 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
HU9301182D0 (en) * 1990-10-25 1993-08-30 Schering Corp Method for producing fluoro-phenicole, its analogues and intermediary compounds
US5158948A (en) * 1990-11-16 1992-10-27 Abbott Laboratories Tetracyclic spirobenzazepine dopamine antagonists
US5476854A (en) 1991-11-27 1995-12-19 Sepracor Inc. Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5883115A (en) 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US6110905A (en) 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
CA2176298C (en) 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US6310053B1 (en) 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5723447A (en) 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
US5958888A (en) 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5663361A (en) 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5755506A (en) * 1996-10-15 1998-05-26 Ray; Eric A. Illuminated badge
SE511313C2 (sv) * 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US6239112B1 (en) 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US5977133A (en) * 1998-08-19 1999-11-02 Abbott Laboratories Pyridone antibiotic with improved safety profile
US7131136B2 (en) * 2002-07-10 2006-10-31 E-Watch, Inc. Comprehensive multi-media surveillance and response system for aircraft, operations centers, airports and other commercial transports, centers and terminals
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
US7332457B2 (en) * 2000-09-18 2008-02-19 Honeywell International Inc. Agricultural chemical suspensions
BR0208790A (pt) * 2001-04-11 2004-03-30 Idenix Cayman Ltd Fenilindoìs para o tratamento de hiv
AU2003249503A1 (en) 2002-03-08 2003-09-29 Schering-Plough, Ltd. Novel florfenicol-type antibiotics
AU2003224265A1 (en) * 2002-04-11 2003-10-27 Powderject Research Limited Nucleic acid immunization
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
US6880956B2 (en) 2003-07-31 2005-04-19 A L Lightech, Inc. Light source with heat transfer arrangement
EP1696934B1 (en) 2003-12-23 2013-05-29 Schering-Plough Ltd. Florfenicol prodrug having improved water solubility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041899A1 (en) * 2000-11-27 2002-05-30 Phoenix Scientific, Inc. An antibiotic/analgesic formulation and a method of making this formulation

Also Published As

Publication number Publication date
US20080090912A1 (en) 2008-04-17
WO2005009429A1 (en) 2005-02-03
EP1651202A1 (en) 2006-05-03
EP2181706A2 (en) 2010-05-05
EP1651202A4 (en) 2006-08-02
US7786167B2 (en) 2010-08-31
US20070142468A1 (en) 2007-06-21
EP2181706A3 (en) 2010-10-06
CA2531223A1 (en) 2005-02-03
US7662861B2 (en) 2010-02-16
JP2006528177A (ja) 2006-12-14
US20080306152A1 (en) 2008-12-11
AU2004258876A1 (en) 2005-02-03
US7439268B2 (en) 2008-10-21
US20050014828A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
US7786167B2 (en) Compositions containing prodrugs of florfenicol and methods of use
EP0593656B1 (fr) Nouvelles compositions a base de derives de la classe des taxanes
US20020058067A1 (en) Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
JP2006528177A5 (cg-RX-API-DMAC10.html)
US9012509B2 (en) Method of treating non-alcoholic steatohepatitis
FR2617171A1 (fr) Nouveaux derives de la somatostatine, leur preparation et leur utilisation comme medicaments
KR20010041358A (ko) 표적 장기 이행성 담체 폴리머 및 약물 함유 폴리머
US5753611A (en) Pharmaceutical composition having site-specific delivery
MC1878A1 (fr) Compositions pharmaceutiques
ES2325005T3 (es) Polisacaridos modificados que muestran un reconocimiento biologico alterado.
US5166328A (en) S-adenosylmethionine derivatives
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
KR100360350B1 (ko) 어포토시스억제제
WO2001036437A1 (fr) DERIVES DE β-D-5-THIOXYLOSE, PROCEDE DE PREPARATION ET UTILISATION EN THERAPEUTIQUE
CH641775A5 (fr) N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment.
CN116966169B (zh) 姜黄素聚乙二醇聚硫化丙烯胶束在制备治疗心脏再灌注损伤药物中的应用
US20260091082A1 (en) Cyclic peptide derivative composition for treating or preventing eye disease
US12239620B2 (en) Methods to decrease triglyceride synthesis in the liver
CN1202826C (zh) 神经障碍治疗剂
FR2534588A2 (fr) Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
CN109021228A (zh) 一种多臂型peg化尿苷三乙酸酯衍生物及其制备
EP0449722B1 (fr) Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés
CN114478494A (zh) 硝基咪唑类化合物的衍生物、药物组合物及其制备方法和应用
BR112018017005B1 (pt) Composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b
LU86243A1 (fr) Enamides acyles et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired